Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $7 | $16 | $9 |
| G&A Expenses | $5 | $6 | $7 | $6 |
| SG&A Expenses | $5 | $6 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $9 | -$2 |
| Operating Expenses | $6 | $13 | $32 | $13 |
| Operating Income | -$6 | -$13 | -$32 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$6 | -$13 | -$32 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$13 | -$32 | -$13 |
| % Margin | – | – | – | – |
| EPS | -86.85 | -0.057 | -221.55 | -930 |
| % Growth | -152,268.4% | 100% | 76.2% | – |
| EPS Diluted | -86.85 | -0.057 | -221.55 | -930 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$13 | -$23 | -$13 |
| % Margin | – | – | – | – |